Biotron Ltd has released a press release.
Zika Virus Program Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Biotron
- Biotron compounds demonstrate activity against Zika virus
- $1.5 Million R&D Tax Rebate
- Trading halt
- Phase 2 Hepatitis C Trial Success
- BIT225 May have a broader role in limiting hiv-1 infection
Later from Biotron
- BIT225 Accelerates HIV-1 Virus Reduction
- $1.6 Million R&D Tax Rebate Received
- BIT225 Phase 2 HIV-1 Clinical Trial Update
- $1.6 Million R&D Tax Incentive Received
- Biotron Compounds Demonstrate Activity Against HBV
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron